250 related articles for article (PubMed ID: 19590177)
1. Advanced glycation end products suppress neuropilin-1 expression in podocytes by a reduction in Sp1-dependent transcriptional activity.
Bondeva T; Wolf G
Am J Nephrol; 2009; 30(4):336-45. PubMed ID: 19590177
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end products inhibit adhesion ability of differentiated podocytes in a neuropilin-1-dependent manner.
Bondeva T; Wojciech S; Wolf G
Am J Physiol Renal Physiol; 2011 Oct; 301(4):F852-70. PubMed ID: 21734098
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the neuropilin-1 promoter; gene expression is mediated by the transcription factor Sp1.
Rossignol M; Pouysségur J; Klagsbrun M
J Cell Biochem; 2003 Mar; 88(4):744-57. PubMed ID: 12577308
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes.
Rüster C; Bondeva T; Franke S; Förster M; Wolf G
Nephrol Dial Transplant; 2008 Jul; 23(7):2179-91. PubMed ID: 18344241
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors.
Rüster C; Bondeva T; Franke S; Tanaka N; Yamamoto H; Wolf G
Am J Nephrol; 2009; 29(6):538-50. PubMed ID: 19129693
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta.
Kim YS; Kim BC; Song CY; Hong HK; Moon KC; Lee HS
J Lab Clin Med; 2001 Jul; 138(1):59-68. PubMed ID: 11433229
[TBL] [Abstract][Full Text] [Related]
7. Impaired transcription factor interplay in addition to advanced glycation end products suppress podocalyxin expression in high glucose-treated human podocytes.
Drossopoulou GI; Tsotakos NE; Tsilibary EC
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F594-603. PubMed ID: 19605546
[TBL] [Abstract][Full Text] [Related]
8. Advanced glycation end-products suppress neuropilin-1 expression in podocytes.
Bondeva T; Rüster C; Franke S; Hammerschmid E; Klagsbrun M; Cohen CD; Wolf G
Kidney Int; 2009 Mar; 75(6):605-16. PubMed ID: 19037249
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of Toll-like receptor 4 gene expression in renal cells by angiotensin II: dependency on AP1 and PU.1 transcriptional sites.
Bondeva T; Roger T; Wolf G
Am J Nephrol; 2007; 27(3):308-14. PubMed ID: 17495427
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin protects podocytes from damage by advanced glycation end-products.
Ruester C; Franke S; Bondeva T; Wolf G
Nephron Exp Nephrol; 2011; 117(1):e21-30. PubMed ID: 20689331
[TBL] [Abstract][Full Text] [Related]
11. Introduction of p16INK4a inhibits telomerase activity through transcriptional suppression of human telomerase reverse transcriptase expression in human gliomas.
Saito M; Nakagawa K; Hamada K; Hirose S; Harada H; Kohno S; Nagato S; Ohnishi T
Int J Oncol; 2004 May; 24(5):1213-20. PubMed ID: 15067344
[TBL] [Abstract][Full Text] [Related]
12. Laminin reduces expression of the human alpha6 integrin subunit gene by altering the level of the transcription factors Sp1 and Sp3.
Gaudreault M; Vigneault F; Leclerc S; Guérin SL
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3490-505. PubMed ID: 17652716
[TBL] [Abstract][Full Text] [Related]
13. Involvement of Sp1 binding sequences in basal transcription of the rat fibroblast growth factor-2 gene in neonatal cardiomyocytes.
Tang W; Pan Q; Sun F; Ma J; Tang S; Le K; Wan Y; Chen Q; Liu P
Life Sci; 2009 Mar; 84(13-14):421-7. PubMed ID: 19302822
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional activity and Sp 1/3 transcription factor binding to the P1 promoter sequences of the human AbetaH-J-J locus.
Feriotto G; Finotti A; Breveglieri G; Treves S; Zorzato F; Gambari R
FEBS J; 2007 Sep; 274(17):4476-90. PubMed ID: 17681019
[TBL] [Abstract][Full Text] [Related]
15. Role of receptor for advanced glycation end-products and signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes.
Gu L; Hagiwara S; Fan Q; Tanimoto M; Kobata M; Yamashita M; Nishitani T; Gohda T; Ni Z; Qian J; Horikoshi S; Tomino Y
Nephrol Dial Transplant; 2006 Feb; 21(2):299-313. PubMed ID: 16263740
[TBL] [Abstract][Full Text] [Related]
16. Sp1 is required for transcriptional activation of the fibroblast growth factor receptor 1 gene in neonatal cardiomyocytes.
Seyed M; Dimario JX
Gene; 2007 Oct; 400(1-2):150-7. PubMed ID: 17628354
[TBL] [Abstract][Full Text] [Related]
17. SP1 regulates a human SNAP-25 gene expression.
Cai F; Chen B; Zhou W; Zis O; Liu S; Holt RA; Honer WG; Song W
J Neurochem; 2008 Apr; 105(2):512-23. PubMed ID: 18194215
[TBL] [Abstract][Full Text] [Related]
18. A point mutation affecting an SP1 binding site in the promoter of the ferrochelatase gene impairs gene transcription and causes erythropoietic protoporphyria.
Di Pierro E; Cappellini MD; Mazzucchelli R; Moriondo V; Mologni D; Zanone Poma B; Riva A
Exp Hematol; 2005 May; 33(5):584-91. PubMed ID: 15850836
[TBL] [Abstract][Full Text] [Related]
19. p53-dependent repression of the human MCL-1 gene encoding an anti-apoptotic member of the BCL-2 family: the role of Sp1 and of basic transcription factor binding sites in the MCL-1 promoter.
Pietrzak M; Puzianowska-Kuznicka M
Biol Chem; 2008 Apr; 389(4):383-93. PubMed ID: 18208354
[TBL] [Abstract][Full Text] [Related]
20. In cardiac myocytes, cAMP elevation triggers the down-regulation of transcripts and promoter activity for cyclic AMP phosphodiesterase-4A10 (PDE4A10).
McCahill A; Campbell L; McSorley T; Sood A; Lynch MJ; Li X; Yan C; Baillie GS; Houslay MD
Cell Signal; 2008 Nov; 20(11):2071-83. PubMed ID: 18721873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
